Xolair 150 mg injection

Reason for shortage

Novartis/Genentech global demand surge for omalizumab across severe asthma and chronic urticaria. Australian allocation under review.

What to do

1. 1.
   Ensure you have adequate stock — Collect your current prescription promptly to build a small buffer before the anticipated shortage begins.
2. 2.
   Speak with your prescriber proactively — Discuss alternative options now, before the shortage occurs, so a plan is in place.
3. 3.
   Monitor TGA updates — Anticipated shortages may be resolved before they become active. Check the TGA MSI database regularly.

Suggested alternatives

Same or related therapeutic class. Always discuss with your doctor or pharmacist before switching.

• Nucala (mepolizumab) — alternative biologic for severe eosinophilic asthma
• Fasenra (benralizumab) — alternative anti-IL-5 biologic